Vitamin K in Chronic Kidney Disease

Mario Cozzolino, Michela Mangano, Andrea Galassi, Paola Ciceri, Piergiorgio Messa, Sagar Nigwekar, Mario Cozzolino, Michela Mangano, Andrea Galassi, Paola Ciceri, Piergiorgio Messa, Sagar Nigwekar

Abstract

Vitamin K is a composite term referring to a group of fat-soluble vitamins that function as a cofactor for the enzyme γ-glutamyl carboxylase (GGCX), which activates a number of vitamin K-dependent proteins (VKDPs) involved in haemostasis and vascular and bone health. Accumulating evidence demonstrates that chronic kidney disease (CKD) patients suffer from subclinical vitamin K deficiency, suggesting that this represents a population at risk for the biological consequences of poor vitamin K status. This deficiency might be caused by exhaustion of vitamin K due to its high requirements by vitamin K-dependent proteins to inhibit calcification.

Keywords: vitamin K, CKD, vascular calcification.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Shearer M.J., Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008;100:530–547.
    1. Booth S.L. Vitamin K: Food composition and dietary intakes. Food Nutr. Res. 2012;56:5505. doi: 10.3402/fnr.v56i0.5505.
    1. Elder S.J., Haytowitz D.B., Howe J., Peterson J.W., Booth S.L. Vitamin K contents of meat, dairy, and fast food in the US diet. J. Agric. Food Chem. 2006;54:463–467. doi: 10.1021/jf052400h.
    1. Sakano T., Nagaoka T., Morimoto A., Hirauchi K. Measurement of K vitamins in human and animal feces by high-performance liquid chromatography with fluorometric detection. Chem. Pharm. Bull. 1986;34:4322–4326. doi: 10.1248/cpb.34.4322.
    1. Ji Y., Li X., Tso P. Intestinal fatty acid absorption. Immununol. Endocr. Metab. Agents Med. Chem. 2009;9:60–73. doi: 10.2174/187152209788009832.
    1. Fusaro M., Gallieni M., Rizzo M.A., Stucchi A., Delanaye P., Cavalier E., Moysés R.M.A., Jorgetti V., Iervasi G., Giannini S., et al. Vitamin K plasma levels determination in human health. Clin. Chem. Lab. Med. 2017;55:789–799. doi: 10.1515/cclm-2016-0783.
    1. Fusaro M., Crepaldi G., Maggi S., Galli F., D’Angelo A., Calò L., Giannini S., Miozzo D., Gallieni M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: An important but poorly studied relationship. J. Endocrinol. Investig. 2011;34:317–323. doi: 10.1007/BF03347093.
    1. Buranasinsup S., Bunyaratavej N. The intriguing correlation between undercarboxylated osteocalcin and vitamin D. J. Med. Assoc. Thail. 2015;98(Suppl. 8):S16–S20.
    1. Caluwé R., Vandecasteele S., Van Vlem B., Vermeer C., De Vriese A.S. Vitamin K2 supplementation in haemodialysis patients: A randomized dose-finding study. Nephrol. Dial. Transplant. 2014;29:1385–1390. doi: 10.1093/ndt/gft464.
    1. Boxma P.Y., van den Berg E., Geleijnse J.M., Laverman G.D., Schurgers L.J., Vermeer C., Kema I.P., Muskiet F.A., Navis G., Bakker S.J., et al. Vitamin K intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS ONE. 2012;7:e47991. doi: 10.1371/journal.pone.0047991.
    1. Westenfeld R., Krueger T., Schlieper G., Cranenburg E.C., Magdeleyns E.J., Heidenreich S., Holzmann S., Vermeer C., Jahnen-Dechent W., Ketteler M., et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am. J. Kidney Dis. 2012;59:186–195. doi: 10.1053/j.ajkd.2011.10.041.
    1. Cranenburg E.C., Koos R., Schurgers L.J., Magdeleyns E.J., Schoonbrood T.H., Landewé R.B. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb. Haemost. 2010;104:811–822. doi: 10.1160/TH09-11-0786.
    1. Delanaye P., Dubois B.E., Lukas P., Peters P., Krzesinski J.M., Pottel H., Cavalier E. Impact of stopping vitamin K antagonist therapy on concentrations of dephospho-uncarboxylated Matrix Gla protein. Clin. Chem. Lab. Med. 2015;53:e191-3. doi: 10.1515/cclm-2015-0073.
    1. Cranenburg E.C.M., Schurgers L.J., Uiterwijk H.H., Beulens J.W., Dalmeijer G.W., Westerhuis R., Magdeleyns E.J., Herfs M., Vermeer C., Laverman G.D. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82:605–610. doi: 10.1038/ki.2012.191.
    1. Bellasi A., Raggi P. Vascular imaging in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2012;21:382–388. doi: 10.1097/MNH.0b013e328354220c.
    1. Schlieper G., Westenfeld R., Krüger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., Djuric Z., Damjanovic T., Ketteler M., Vermeer C., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J. Am. Soc. Nephrol. 2011;22:387–395. doi: 10.1681/ASN.2010040339.
    1. Shea M.K., O’Donnell C.J., Vermeer C., Magdeleyns E.J., Crosier M.D., Gundberg C.M., Ordovas J.M., Kritchevsky S.B., Booth S.L. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J. Nutr. 2011;141:1529–1534. doi: 10.3945/jn.111.139634.
    1. Schurgers L.J., Barreto D.V., Barreto F.C., Liabeuf S., Renard C., Magdeleyns E.J., Vermeer C., Choukroun G., Massy Z.A. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin. J. Am. Soc. Nephrol. 2010;5:568–575. doi: 10.2215/CJN.07081009.
    1. McCabe K., Booth S., Fu X., Shobeiri N., Pang J., Adams M., Holden R. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83:835–844. doi: 10.1038/ki.2012.477.
    1. Holden R.M., Morton A.R., Garland J.S., Pavlov A., Day A.G., Booth S.L. Vitamins K and D status in stages 3–5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010;5:590–597. doi: 10.2215/CJN.06420909.
    1. McCabe K.M., Adams M.A., Holden R.M. Vitamin K status in chronic kidney disease. Nutrients. 2013;5:4390–4398. doi: 10.3390/nu5114390.
    1. Voong K., Harrington D., Goldsmith D. Vitamin K status in chronic kidney disease: A report of a study and a mini-review. Int. Urol. Nephrol. 2013;45:1339–1344. doi: 10.1007/s11255-012-0367-x.
    1. Stankowiak-Kulpa H., Krzyzanowska P., Koziol L., Grzymislawski M., Wanic-Kossowska M., Moczko J., Walkowiak J. Vitamin K status in peritoneally dialyzed patients with chronic kidney disease. Acta Biochim. Pol. 2011;58:617–620.
    1. Holden R.M., Iliescu E., Morton A.R., Booth S.L. Vitamin K status of canadian peritoneal dialysis patients. Perit. Dial. Int. 2008;28:415–418.
    1. Jansz T.T., Neradova A., van Ballegooijen A.J., Verhaar M.C., Vervloet M.G., Schurgers L.J., van Jaarsveld B.C. The role of kidney transplantation and phosphate binder use in vitamin K status. PLoS ONE. 2018;13:e0203157. doi: 10.1371/journal.pone.0203157.
    1. Tantisattamo E., Han K.H., O’Neill W.C. Increased vascular calcification in patients receiving warfarin. Arterioscler. Thromb. Vasc. Biol. 2015;35:237–242. doi: 10.1161/ATVBAHA.114.304392.
    1. Rodriguez-Garcia M., Gomez-Alonso C., Naves-Diaz M., Díaz López J.B., Megido J., Gago E., Forascepi R., Cannata Andía J.B. Prevalence of vertebral fractures and aortic calcifications in hemodialysis patients: Comparison with a population of the same age and sex. Nefrologia. 2003;23(Suppl. 2):106–111.
    1. Jamal S.A., Gilbert J., Gordon C., Bauer D.C. Cortical pQCT measures are associated with fractures in dialysis patients. J. Bone Miner. Res. 2006;21:543–548. doi: 10.1359/jbmr.060105.
    1. Rodriguez-Garcia M., Gomez-Alonso C., Naves-Diaz M., Diaz-Lopez J.B., Diaz-Corte C., Cannata-Andia J.B., Asturias Study Group Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol. Dial. Transplant. 2009;24:239–246. doi: 10.1093/ndt/gfn466.
    1. Alem A.M., Sherrard D.J., Gillen D.L., Weiss N.S., Beresford S.A., Heckbert S.R., Wong C., Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–399. doi: 10.1046/j.1523-1755.2000.00178.x.
    1. Kohlmeier M., Saupe J., Shearer M.J., Schaefer K., Asmus G. Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int. 1997;51:1218–1221. doi: 10.1038/ki.1997.166.
    1. Fusaro M., Noale M., Viola V., Galli F., Tripepi G., Vajente N., Plebani M., Zaninotto M., Guglielmi G., Miotto D., et al. VItamin K Italian (VIKI) dialysis study investigators. Vitamin K, vertebral fractures, vascular calcifications, and mortality: Vitamin K Italian (VIKI) dialysis study. J. Bone Miner. Res. 2012;27:2271–2278. doi: 10.1002/jbmr.1677.
    1. Fusaro M., Tripepi G., Noale M., Plebani M., Zaninotto M., Piccoli A., Naso A., Miozzo D., Giannini S., Avolio M., et al. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. Curr. Vasc. Pharmacol. 2013;13:248–258. doi: 10.2174/15701611113119990146.
    1. Cockayne S., Adamson J., Lanham-New S., Shearer M.J., Gilbody S., Torgerson D.J. Vitamin K and prevention of fractures: Systematic review and meta-analysis of randomized controlled trials. Arch. Intern. Med. 2006;166:1256–1261. doi: 10.1001/archinte.166.12.1256.
    1. Schurgers L.J., Aebert H., Vermeer C., Bultmann B., Janzen J. Oral anticoagulant treatment: Friend or foe in cardiovascular disease? Blood. 2004;104:3231–3232. doi: 10.1182/blood-2004-04-1277.
    1. Koos R., Mahnken A.H., Muhlenbruch G., Brandenburg V., Pflueger B., Wildberger J.E., Kuhl H.P. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am. J. Cardiol. 2005;96:747–749. doi: 10.1016/j.amjcard.2005.05.014.
    1. Hristova M., van Beek C., Schurgers L.J., Lanske B., Danziger J. Rapidly progressive severe vascular calcification sparing the kidney allograft following warfarin initiation. Am. J. Kidney Dis. 2010;56:1158–1162. doi: 10.1053/j.ajkd.2010.06.017.
    1. Rennenberg R.J., van Varik B.J., Schurgers L.J., Hamulyak K., Ten Cate H., Leiner T., Vermeer C., de Leeuw P.W., Kroon A.A. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood. 2010;115:5121–5123. doi: 10.1182/blood-2010-01-264598.
    1. Weijs B., Blaauw Y., Rennenberg R.J., Schurgers L.J., Timmermans C.C., Pison L., Nieuwlaat R., Hofstra L., Kroon A.A., Wildberger J., et al. Patients using vitamin K antagonists show increased levels of coronary calcification: An observational study in low-risk atrial fibrillation patients. Eur. Heart J. 2011;32:2555–2562. doi: 10.1093/eurheartj/ehr226.
    1. Chatrou M.L.L., Winckers K., Hackeng T.M., Reutelingsperger C.P., Schurgers L.J. Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012;26:155–166. doi: 10.1016/j.blre.2012.03.002.
    1. Hayashi M., Takamatsu I., Kanno Y., Yoshida T., Abe T., Sato Y., Japanese Calciphylaxis Study Group A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol. Dial. Transplant. 2012;27:1580–1584. doi: 10.1093/ndt/gfr658.
    1. Nigwekar S.U., Bloch D.B., Nazarian R.M., Vermeer C., Booth S.L., Xu D., Thadhani R.I., Malhotra R. Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis. J. Am. Soc. Nephrol. 2017;28:1717–1722. doi: 10.1681/ASN.2016060651.
    1. Krueger T., Westenfeld R., Schurgers L., Brandenburg V. Coagulation meets calcification: The vitamin K system. Int. J. Artif. Organs. 2009;32:67–74. doi: 10.1177/039139880903200202.
    1. Pisoni R.L., Young E.W., Dykstra D.M., Greenwood R.N., Hecking E., Gillespie B., Wolfe R.A., Goodkin D.A., Held P.J. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int. 2002;61:305–316. doi: 10.1046/j.1523-1755.2002.00117.x.
    1. Schwab S.J., Harrington J.T., Singh A., Roher R., Shohaib S.A., Perrone R.D., Meyer K., Beasley D. Vascular access for hemodialysis. Kidney Int. 1999;55:2078–2090. doi: 10.1046/j.1523-1755.1999.00409.x.
    1. Lemson M.S., Tordoir J.H., Daemen M.J.A.P., Kitslaar P.J.E.H.M. Intimal hyperplasia in vascular grafts. Eur. J. Vasc. Endovasc. Surg. 2000;19:336–350. doi: 10.1053/ejvs.1999.1040.
    1. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., Wang Y., Chung J., Emerick A., Greaser L., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000;342:1478–1483. doi: 10.1056/NEJM200005183422003.
    1. Balci M., Kirkpantur A., Turkvatan A., Mandıroglu S., Ozturk E., Afsar B. Sclerostin as a new key player in arteriovenous fistula calcification. Herz. 2013;40:289–297. doi: 10.1007/s00059-013-3992-y.
    1. Diener H.C., Hajjar K., Frank B., Perrey M. New anticoagulants for stroke prevention in atrial fibrillation. Herz. 2012;37:370–377. doi: 10.1007/s00059-012-3617-x.
    1. Cario-Toumaniantz C., Boularan C., Schurgers L.J., Le Cunff M., Léger J., Loirand G., Pacaud P. Identification of differentially expressed genes in human varicose veins: Involvement of matrix gla protein in extracellular matrix remodeling. J. Vasc. Res. 2007;44:444–459. doi: 10.1159/000106189.
    1. Zaragatski E., Grommes J., Schurgers L.J., Langer S., Kennes L., Tamm M., Koeppel T.A., Kranz J., Hackhofer T., Arakelyan K., et al. Vitamin K antagonism aggravates aggravates chronic kidney disease-induced neointimal hyperplasia and calcification in arterialized veins: Role of vitamin K tratment? Kidney Int. 2016;89:601–611. doi: 10.1038/ki.2015.298.
    1. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638.
    1. Chan K.E., Edelman E.R., Wenger J.B., Thadhani R.I., Maddux F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972–979. doi: 10.1161/CIRCULATIONAHA.114.014113.
    1. Siontis K.C., Zhang X., Eckard A., Bhave N., Schaubel D.E., He K., Tilea A., Stack A.G., Balkrishnan R., Yao X., et al. Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States. Circulation. 2018 doi: 10.1161/CIRCULATIONAHA.118.035418.
    1. Cozzolino M., Mangano M., Magagnoli L., Di Lullo L., Galassi A., Brancaccio D., Bellasi A. Iron-based Phosphate Binders for ESRD Patients G Ital Nefrol. Giornale italiano di nefrologia: Organo ufficiale della Societa italiana di nefrologia. 2016;33:27545638.
    1. Palmer S.C., Gardner S., Tonelli M., Mavridis D., Johnson D.W., Craig J.C., French R., Ruospo M., Strippoli G.F. Phosphate-binding agents in adults with CKD: A network meta-analysis of randomized trials. Am. J. Kidney Dis. 2016;68:691–702. doi: 10.1053/j.ajkd.2016.05.015.
    1. Ohtake T., Kobayashi S., Oka M., Furuya R., Iwagami M., Tsutsumi D., Mochida Y., Maesato K., Ishioka K., Moriya H., et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: A pilot study. J. Cardiovasc. Pharmacol. Ther. 2013;18:439–446. doi: 10.1177/1074248413486355.
    1. Raggi P., Bommer J., Chertow G.M. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J. Heart Valve Dis. 2004;13:134–141.
    1. Chertow G.M., Burke S.K., Raggi P., Treat to Goal Working Group Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252. doi: 10.1046/j.1523-1755.2002.00434.x.
    1. Neradova A., Schumacher S.P., Hubeek I., Lux P., Schurgers L.J., Vervloet M.G. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol. 2017;18:149. doi: 10.1186/s12882-017-0560-3.
    1. Fusaro M., Giannini S., Gallieni M., Noale M., Tripepi G., Rossini M., Messa P., Rigotti P., Pati T., Barbisoni F., et al. Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increasedlevels of vitamin K dependent proteins. Endocrine. 2016;51:333–341. doi: 10.1007/s12020-015-0673-z.
    1. Rodriguez M., Aguilera-Tejero E., Mendoza F.J., Guerrero F., López I. Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney Int. 2008;74(Suppl. 111):S50–S54. doi: 10.1038/ki.2008.546.
    1. Mendoza F.J., Martinez-Moreno J., Almaden Y., Rodriguez-Ortiz M.E., Lopez I., Estepa J.C., Henley C., Rodriguez M., Aguilera-Tejero E. Effect of calcium and the calcimimetic AMG 641 on matrix-GIa protein in vascular smooth musclecells. Calcif. Tissue Int. 2011;88:169–178. doi: 10.1007/s00223-010-9442-4.
    1. Torbergsen A.C., Watne L.O., Wyller T.B., Frihagen F., Strømsøe K., Bøhmer T., Mowe M. Vitamin K1 and 25(OH)D are independently and synergistically associated with a risk for hipfracture in an elderly population: A case control study. Clin. Nutr. 2015;34:101–106. doi: 10.1016/j.clnu.2014.01.016.
    1. Geleijnse J.M., Vermeer C., Grobbee D.E., Schurgers L.J., Knapen M.H., van der Meer I.M., Hofman A., Witteman J.C. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J. Nutr. 2004;134:3100–3105. doi: 10.1093/jn/134.11.3100.
    1. Shea M.K., O’Donnell C.J., Hoffmann U., Dallal G.E., Dawson-Hughes B., Ordovas J.M., Price P.A., Williamson M.K., Booth S.L. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am. J. Clin. Nutr. 2009;89:1799–1807. doi: 10.3945/ajcn.2008.27338.
    1. Keyzer C.A., Vermeer C., Joosten M.M., Knapen M.H., Drummen N.E., Navis G., Bakker S.J., de Borst M.H. Vitamin K status and mortality after kidney transplantation: A cohort study. Am. J. Kidney Dis. 2015;65:474–483. doi: 10.1053/j.ajkd.2014.09.014.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다